Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STARTMRK: Raltegravir vs Efavirenz in Treatment-Naive HIV
NCT00369941Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Aug 2006
- Primary completion
- May 2009
- Modality
- Small Molecules
01
Overview
A Phase 3 trial of raltegravir in human immunodeficiency virus infection (HIV), sponsored by Merck & Co.. Started Aug 2006; status: completed.
02
Drugs
raltegravir
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT00369941.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00369941.